Celastrol: A spectrum of treatment opportunities in chronic diseases

Frontiers in Medicine

Volumn 4, Issue JUN, 2017, Pages

  Cascão, Rita ^a   Fonseca, João E ^a,b   Moita, Luis F ^c  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

Cancer; Celastrol; Clinical trials; Inflammation; Neurodegenerative diseases; Toxicity; Treatment

Indexed keywords

EID: 85037138841     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2017.00069     Document Type: Review

References (220)

1. Bakar MH, Sarmidi MR, Kai CK, Huri HZ, Yaakob H. Amelioration of mitochondrial dysfunction-induced insulin resistance in differentiated 3T3-L1 adipocytes via inhibition of NF-kappaB pathways. Int J Mol Sci (2014) 15(12):22227-57. doi: 10.3390/ijms151222227
2. Ren J, Tao Q, Wang X, Wang Z, Li J. Efficacy of T2 in active Crohn's disease: a prospective study report. Dig Dis Sci (2007) 52(8):1790-7. doi:10.1007/s10620-007-9747-y
3. Tao QS, Ren JA, Ji ZL, Li JS, Wang XB, Jiang XH. [Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease]. Zhonghua Wei Chang Wai Ke Za Zhi (2009) 12(5):491-3
4. Liao NS, Ren JA, Fan CG, Wang GF, Zhao YZ, Li JS. [Efficacy of polyglycosides of Tripterygium wilfordii in preventing postoperative recurrence of Crohn disease]. Zhonghua Wei Chang Wai Ke Za Zhi (2009) 12(2):167-9
5. Ren J, Wu X, Liao N, Wang G, Fan C, Liu S, et al. Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine. J Int Med Res (2013) 41(1):176-87. doi:10.1177/0300060512474744
6. Zhu W, Li Y, Gong J, Zuo L, Zhang W, Cao L, et al. Tripterygium wilfordii Hook. F. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. Dig Liver Dis (2015) 47(1):14-9. doi:10.1016/j.dld.2014.09.008
7. Sun J, Shen X, Dong J, Wang H, Zuo L, Zhao J, et al. Tripterygium wilfordii Hook F as maintenance treatment for Crohn's disease. Am J Med Sci (2015) 350(5):345-51. doi:10.1097/MAJ.0000000000000591
8. Wu C, Jin HZ, Shu D, Li F, He CX, Qiao J, et al. Efficacy and safety of Tripterygium wilfordii Hook F versus acitretin in moderate to severe psoriasis vulgaris: a randomized clinical trial. Chin Med J (Engl) (2015) 128(4):443-9. doi:10.4103/0366-6999.151069
9. Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum (2002) 46(7):1735-43. doi:10.1002/art.10411
10. Jiang Q, Cao W, Tang X, Jiao J. [Tripterygium wilfordii extract for treating rheumatoid arthritis: systematic review]. Zhongguo Zhong Yao Za Zhi (2009) 34(20):2637-43
11. Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med (2009) 151(4):229-40. doi:10.7326/0003-4819-151-4-200908180-00005W49-51
12. Jiao J, Jiang Q. [External application of compound Tripterygium wilfordii decreased the activity of rheumatoid arthritis]. Zhongguo Zhong Xi Yi Jie He Za Zhi (2012) 32(11):1470-2. 6
13. Cibere J, Deng Z, Lin Y, Ou R, He Y, Wang Z, et al. A randomized double blind, placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: reanalysis using logistic regression analysis. J Rheumatol (2003) 30(3):465-7
14. Liu Y, Tu S, Gao W, Wang Y, Liu P, Hu Y, et al. Extracts of Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: a systemic review and meta-analysis of randomised controlled trials. Evid Based Complement Alternat Med (2013) 2013:410793. doi:10.1155/2013/410793
15. Zhang C, Jiang M, He XJ, Lu AP. Clinical trials of integrative medicine for rheumatoid arthritis: issues and recommendations. Chin J Integr Med (2015) 21(6):403-7. doi:10.1007/s11655-015-2041-5
16. Lv QW, Zhang W, Shi Q, Zheng WJ, Li X, Chen H, et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Ann Rheum Dis (2015) 74(6):1078-86. doi:10.1136/annrheumdis-2013-204807
17. Alarcon GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum (1989) 32(6):671-6. doi:10.1002/anr.1780320603
18. Wu YJ, Lao ZY, Zhang ZL. [Clinical observation on small doses Tripterygium wilfordii polyglycoside combined with methotrexate in treating rheumatoid arthritis]. Zhongguo Zhong Xi Yi Jie He Za Zhi (2001) 21(12):895-6
19. He WZ, Yin ZH, Gao JH, Ye ZZ, Xie Y, Kong WH, et al. [Etanercept combined with Tripterygium wilfordii polyglycoside for treatment of rheumatoid arthritis in the elderly: a clinical study]. Zhongguo Zhong Xi Yi Jie He Za Zhi (2014) 34(3):267-71
20. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res (2002) 8(8):2666-74
21. Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der Biessen D, van Doorn L, et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer (2009) 45(10):1764-72. doi:10.1016/j.ejca.2009.01.026
22. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology (2006) 67(1):20-7. doi:10.1212/01.wnl.0000223353.34006.54
23. Ma RX, Zhao N, Zhang W. [The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients]. Zhonghua Nei Ke Za Zhi (2013) 52(6):469-73
24. Ge Y, Xie H, Li S, Jin B, Hou J, Zhang H, et al. Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial. J Transl Med (2013) 11:134. doi:10.1186/1479-5876-11-134
25. Zhu B, Wang Y, Jardine M, Jun M, Lv JC, Cass A, et al. Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis. Am J Kidney Dis (2013) 62(3):515-30. doi:10.1053/j.ajkd.2013.02.374
26. Ji SM, Wang QW, Chen JS, Sha GZ, Liu ZH, Li LS. Clinical trial of Tripterygium Wilfordii Hook F. in human kidney transplantation in China. Transplant Proc (2006) 38(5):1274-9. doi:10.1016/j.transproceed.2006.03.017
27. Qian SZ. Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. Contraception (1987) 36(3):335-45. doi:10.1016/0010-7824(87)90104-1
28. Matlin SA, Belenguer A, Stacey VE, Qian SZ, Xu Y, Zhang JW, et al. Male antifertility compounds from Tripterygium wilfordii Hook F. Contraception (1993) 47(4):387-400. doi:10.1016/0010-7824(93)90036-7
29. Yuan YY, Gu ZP, Shi QX, Qin GW, Xu RS, Cao L. [In vitro inhibition of celastrol on spermatozoa fertilization ability of guinea pig]. Yao Xue Xue Bao (1995) 30(5):331-5
30. Xu WM, Zhang LX, Cheng ZH, Cai WZ, Miao HH, Pan DJ. [Inhibitory effect of tripterine on activities of IL-1, IL-2 and release of PGE2]. Yao Xue Xue Bao (1991) 26(9):641-5
31. Li H, Jia YF, Pan Y, Pan DJ, Li D, Zhang LX. Effect of tripterine on collagen-induced arthritis in rats. Zhongguo Yao Li Xue Bao (1997) 18(3):270-3
32. Li H, Zhang YY, Tan HW, Jia YF, Li D. Therapeutic effect of tripterine on adjuvant arthritis in rats. J Ethnopharmacol (2008) 118(3):479-84. doi:10.1016/j.jep.2008.05.028
33. Kim DH, Shin EK, Kim YH, Lee BW, Jun JG, Park JH, et al. Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. Eur J Clin Invest (2009) 39(9):819-27. doi:10.1111/j.1365-2362.2009.02186.x
34. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, et al. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol (2006) 72(10):1311-21. doi:10.1016/j.bcp.2006.08.014
35. Venkatesha SH, Yu H, Rajaiah R, Tong L, Moudgil KD. Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. J Biol Chem (2011) 286(17):15138-46. doi:10.1074/jbc.M111.226365
36. Venkatesha SH, Astry B, Nanjundaiah SM, Yu H, Moudgil KD. Suppression of autoimmune arthritis by Celastrus-derived celastrol through modulation of pro-inflammatory chemokines. Bioorg Med Chem (2012) 20(17):5229-34. doi:10.1016/j.bmc.2012.06.050
37. Haas CS, Martinez RJ, Attia N, Haines GK III, Campbell PL, Koch AE. Chemokine receptor expression in rat adjuvant-induced arthritis. Arthritis Rheum (2005) 52(12):3718-30. doi:10.1002/art.21476
38. Shahrara S, Amin MA, Woods JM, Haines GK, Koch AE. Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis. Arthritis Rheum (2003) 48(12):3568-83. doi:10.1002/art.11344
39. Cascao R, Vidal B, Raquel H, Neves-Costa A, Figueiredo N, Gupta V, et al. Effective treatment of rat adjuvant-induced arthritis by celastrol. Autoimmun Rev (2012) 11(12):856-62. doi:10.1016/j.autrev.2012.02.022
40. Cascao R, Vidal B, Lopes IP, Paisana E, Rino J, Moita LF, et al. Decrease of CD68 synovial macrophages in celastrol treated arthritic rats. PLoS One (2015) 10(12):e0142448. doi:10.1371/journal.pone.0142448
41. Lee JY, Lee BH, Kim ND, Lee JY. Celastrol blocks binding of lipopolysaccharides to a toll-like receptor4/myeloid differentiation factor2 complex in a thiol-dependent manner. J Ethnopharmacol (2015) 172:254-60. doi:10.1016/j.jep.2015.06.028
42. Li G, Liu D, Zhang Y, Qian Y, Zhang H, Guo S, et al. Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-kappaB-mediated matrix metalloproteinase-9 expression. PLoS One (2013) 8(7):e68905. doi:10.1371/journal.pone.0068905
43. Li GQ, Zhang Y, Liu D, Qian YY, Zhang H, Guo SY, et al. Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression. Int Immunopharmacol (2012) 14(4):422-31. doi:10.1016/j.intimp.2012.08.016
44. Li GQ, Liu D, Zhang Y, Qian YY, Zhu YD, Guo SY, et al. Anti-invasive effects of celastrol in hypoxia-induced fibroblast-like synoviocyte through suppressing of HIF-1alpha/CXCR4 signaling pathway. Int Immunopharmacol (2013) 17(4):1028-36. doi:10.1016/j.intimp.2013.10.006
45. Yu Y, Koehn CD, Yue Y, Li S, Thiele GM, Hearth-Holmes MP, et al. Celastrol inhibits inflammatory stimuli-induced neutrophil extracellular trap formation. Curr Mol Med (2015) 15(4):401-10. doi:10.2174/1566524015666150505160743
46. Astry B, Venkatesha SH, Laurence A, Christensen-Quick A, Garzino-Demo A, Frieman MB, et al. Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ. Clin Immunol (2015) 157(2):228-38. doi:10.1016/j.clim.2015.01.011
47. Idris AI, Krishnan M, Simic P, Landao-Bassonga E, Mollat P, Vukicevic S, et al. Small molecule inhibitors of IkappaB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. FASEB J (2010) 24(11):4545-55. doi:10.1096/fj.10-164095
48. Nanjundaiah SM, Venkatesha SH, Yu H, Tong L, Stains JP, Moudgil KD. Celastrus and its bioactive celastrol protect against bone damage in autoimmune arthritis by modulating osteoimmune cross-talk. J Biol Chem (2012) 287(26):22216-26. doi:10.1074/jbc.M112.356816
49. Gan K, Xu L, Feng X, Zhang Q, Wang F, Zhang M, et al. Celastrol attenuates bone erosion in collagen-Induced arthritis mice and inhibits osteoclast differentiation and function in RANKL-induced RAW264.7. Int Immunopharmacol (2015) 24(2):239-46. doi:10.1016/j.intimp.2014.12.012
50. Liu X, Cai F, Zhang Y, Yang A, Liu L. Celastrol, an NF-kappaB inhibitor, ameliorates hypercalciuria and articular cartilage lesions in a mouse model of secondary osteoporosis. J Pharmacol Sci (2016) 130(4):204-11. doi:10.1016/j.jphs.2016.02.001
51. Braun J, Sieper J. Ankylosing spondylitis. Lancet (2007) 369(9570):1379-90. doi:10.1016/S0140-6736(07)60635-7
52. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum (2008) 58(3):649-56. doi:10.1002/art.23260
53. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res (1995) 313:36-46
54. Ramirez-Yanez GO, Seymour GJ, Walsh LJ, Forwood MR, Symons AL. Prostaglandin E2 enhances alveolar bone formation in the rat mandible. Bone (2004) 35(6):1361-8. doi:10.1016/j.bone.2004.08.006
55. Flanagan AM, Chambers TJ. Stimulation of bone nodule formation in vitro by prostaglandins E1 and E2. Endocrinology (1992) 130(1):443-8. doi:10.1210/endo.130.1.1309342
56. Tao X, Schulze-Koops H, Ma L, Cai J, Mao Y, Lipsky PE. Effects of Tripterygium wilfordii Hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum (1998) 41(1):130-8. doi:10.1002/1529-0131(199801)41:1<130::AID-ART16>3.3.CO;2-W
57. Zou YC, Yang XW, Yuan SG, Zhang P, Li YK. Celastrol inhibits prostaglandin E2-induced proliferation and osteogenic differentiation of fibroblasts isolated from ankylosing spondylitis hip tissues in vitro. Drug Des Devel Ther (2016) 10:933-48. doi:10.2147/DDDT.S97463
58. Yang L, Li Y, Ren J, Zhu C, Fu J, Lin D, et al. Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2. Int J Mol Sci (2014) 15(8):13637-48. doi:10.3390/ijms150813637
59. Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids (2002) 66(2-3):243-56. doi:10.1054/plef.2001.0362
60. Xu X, Wu Z, Xu C, Ren Y, Ge Y. Observation on serum anti-double stranded DNA antibodies of tripterine in systemic lupus erythematosus of (NZBxW)F1 mice. Ann Rheum Dis (2003) 62(4):377-8. doi:10.1136/ard.62.4.377
61. Li H, Zhang YY, Huang XY, Sun YN, Jia YF, Li D. Beneficial effect of tripterine on systemic lupus erythematosus induced by active chromatin in BALB/c mice. Eur J Pharmacol (2005) 512(2-3):231-7. doi:10.1016/j.ejphar.2005.02.030
62. Elson CO. Genes, microbes, and T cells-new therapeutic targets in Crohn's disease. N Engl J Med (2002) 346(8):614-6. doi:10.1056/NEJM200202213460812
63. Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med (2002) 8(6):567-73. doi:10.1038/nm0602-567
64. Pinna GF, Fiorucci M, Reimund JM, Taquet N, Arondel Y, Muller CD. Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun (2004) 322(3):778-86. doi:10.1016/j.bbrc.2004.07.186
65. Shaker ME, Ashamallah SA, Houssen ME. Celastrol ameliorates murine colitis via modulating oxidative stress, inflammatory cytokines and intestinal homeostasis. Chem Biol Interact (2014) 210:26-33. doi:10.1016/j.cbi.2013.12.007
66. Jia Z, Xu C, Shen J, Xia T, Yang J, He Y. The natural compound celastrol inhibits necroptosis and alleviates ulcerative colitis in mice. Int Immunopharmacol (2015) 29(2):552-9. doi:10.1016/j.intimp.2015.09.029
67. Bushell KN, Leeman SE, Gillespie E, Gower AC, Reed KL, Stucchi AF, et al. LITAF mediation of increased TNF-alpha secretion from inflamed colonic lamina propria macrophages. PLoS One (2011) 6(9):e25849. doi:10.1371/journal.pone.0025849
68. Zhao J, Sun Y, Shi P, Dong JN, Zuo LG, Wang HG, et al. Celastrol ameliorates experimental colitis in IL-10 deficient mice via the up-regulation of autophagy. Int Immunopharmacol (2015) 26(1):221-8. doi:10.1016/j.intimp.2015.03.033
69. Lin L, Sun Y, Wang D, Zheng S, Zhang J, Zheng C. Celastrol ameliorates ulcerative colitis-related colorectal cancer in mice via suppressing inflammatory responses and epithelial-mesenchymal transition. Front Pharmacol (2015) 6:320. doi:10.3389/fphar.2015.00320
70. Wang R, Gu X, Dai W, Ye J, Lu F, Chai Y, et al. A lipidomics investigation into the intervention of celastrol in experimental colitis. Mol Biosyst (2016) 12(5):1436-44. doi:10.1039/c5mb00864f
71. Ding QH, Cheng Y, Chen WP, Zhong HM, Wang XH. Celastrol, an inhibitor of heat shock protein 90beta potently suppresses the expression of matrix metalloproteinases, inducible nitric oxide synthase and cyclooxygenase-2 in primary human osteoarthritic chondrocytes. Eur J Pharmacol (2013) 708(1-3):1-7. doi:10.1016/j.ejphar.2013.01.057
72. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol (2003) 111(2):227-42. doi:10.1067/mai.2003.139 quiz 43
73. Kumagai K, Ohno I, Okada S, Ohkawara Y, Suzuki K, Shinya T, et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol (1999) 162(7):4212-9
74. Lanone S, Zheng T, Zhu Z, Liu W, Lee CG, Ma B, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and-12 in IL-13-induced inflammation and remodeling. J Clin Invest (2002) 110(4):463-74. doi:10.1172/JCI0214136
75. Liu RL, Liu ZL, Li Q, Qiu ZM, Lu HJ, Yang ZM, et al. [The experimental study on the inhibitory effect of tripterine on airway inflammation in asthmatic mice]. Zhonghua Jie He He Hu Xi Za Zhi (2004) 27(3):165-8
76. Kim DY, Park JW, Jeoung D, Ro JY. Celastrol suppresses allergen-induced airway inflammation in a mouse allergic asthma model. Eur J Pharmacol (2009) 612(1-3):98-105. doi:10.1016/j.ejphar.2009.03.078
77. Kim Y, Kim K, Lee H, Han S, Lee YS, Choe J, et al. Celastrol binds to ERK and inhibits FcepsilonRI signaling to exert an anti-allergic effect. Eur J Pharmacol (2009) 612(1-3):131-42. doi:10.1016/j.ejphar.2009.03.071
78. Li HY, Zhang J, Sun LL, Li BH, Gao HL, Xie T, et al. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study. Cell Death Dis (2015) 6:e1604. doi:10.1038/cddis.2014.543
79. Lee HW, Jang KS, Choi HJ, Jo A, Cheong JH, Chun KH. Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy. BMB Rep (2014) 47(12):697-702. doi:10.5483/BMBRep.2014.47.12.069
80. Sha M, Ye J, Zhang LX, Luan ZY, Chen YB, Huang JX. Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K/Akt-NF-kappaB signaling pathway. Pharmacology (2014) 93(1-2):39-46. doi:10.1159/000357683
81. Sha M, Ye J, Luan ZY, Guo T, Wang B, Huang JX. Celastrol induces cell cycle arrest by MicroRNA-21-mTOR-mediated inhibition p27 protein degradation in gastric cancer. Cancer Cell Int (2015) 15:101. doi:10.1186/s12935-015-0256-3
82. Guo J, Huang X, Wang H, Yang H. Celastrol induces autophagy by targeting AR/miR-101 in prostate cancer cells. PLoS One (2015) 10(10):e0140745. doi:10.1371/journal.pone.0140745
83. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 10(4):321-30. doi:10.1016/j.ccr.2006.09.005
84. Yang H, Murthy S, Sarkar FH, Sheng S, Reddy GP, Dou QP. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol (2008) 217(3):569-76. doi:10.1002/jcp.21565
85. Han X, Sun S, Zhao M, Cheng X, Chen G, Lin S, et al. Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1alpha protein synthesis. PLoS One (2014) 9(11):e112470. doi:10.1371/journal.pone.0112470
86. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther (2008) 7(1):162-70. doi:10.1158/1535-7163.MCT-07-0484
87. Sreeramulu S, Gande SL, Gobel M, Schwalbe H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl (2009) 48(32):5853-5. doi:10.1002/anie.200900929
88. Chadli A, Felts SJ, Wang Q, Sullivan WP, Botuyan MV, Fauq A, et al. Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the co-chaperone p23. J Biol Chem (2010) 285(6):4224-31. doi:10.1074/jbc.M109.081018
89. Zanphorlin LM, Alves FR, Ramos CH. The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90kDa heat shock protein Hsp90alpha, a chaperone implicated in the stabilization of the tumor phenotype. Biochim Biophys Acta (2014) 1840(10):3145-52. doi:10.1016/j.bbagen.2014.06.008
90. Sung B, Park B, Yadav VR, Aggarwal BB. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem (2010) 285(15):11498-507. doi:10.1074/jbc.M109.090209
91. Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, Lu W, et al. Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett (2010) 297(2):155-64. doi:10.1016/j.canlet.2010.04.030
92. Mou H, Zheng Y, Zhao P, Bao H, Fang W, Xu N. Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria-and Fas/FasL-mediated pathways. Toxicol In Vitro (2011) 25(5):1027-32. doi:10.1016/j.tiv.2011.03.023
93. Chen G, Zhang X, Zhao M, Wang Y, Cheng X, Wang D, et al. Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. BMC Cancer (2011) 11:170. doi:10.1186/1471-2407-11-170
94. Yu X, Zhou X, Fu C, Wang Q, Nie T, Zou F, et al. Celastrol induces apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway. Oncol Rep (2015) 34(3):1129-36. doi:10.3892/or.2015.4124
95. Li PP, He W, Yuan PF, Song SS, Lu JT, Wei W. Celastrol induces mitochondria-mediated apoptosis in hepatocellular carcinoma Bel-7402 cells. Am J Chin Med (2015) 43(1):137-48. doi:10.1142/S0192415X15500093
96. Shrivastava S, Jeengar MK, Reddy VS, Reddy GB, Naidu VG. Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. Exp Mol Pathol (2015) 98(3):313-27. doi:10.1016/j.yexmp.2015.03.031
97. Lee JH, Won YS, Park KH, Lee MK, Tachibana H, Yamada K, et al. Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT signaling. Apoptosis (2012) 17(12):1275-86. doi:10.1007/s10495-012-0767-5
98. Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A, et al. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis (2011) 16(10):1028-41. doi:10.1007/s10495-011-0629-6
99. Kim JH, Lee JO, Lee SK, Kim N, You GY, Moon JW, et al. Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway. Cell Signal (2013) 25(4):805-13. doi:10.1016/j.cellsig.2012.12.005
100. Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, et al. Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther (2011) 11(2):263-76. doi:10.4161/cbt.11.2.13959
101. Jang SY, Jang SW, Ko J. Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor alpha. Cancer Lett (2011) 300(1):57-65. doi:10.1016/j.canlet.2010.09.006
102. Yang HS, Kim JY, Lee JH, Lee BW, Park KH, Shim KH, et al. Celastrol isolated from Tripterygium regelii induces apoptosis through both caspase-dependent and-independent pathways in human breast cancer cells. Food Chem Toxicol (2011) 49(2):527-32. doi:10.1016/j.fct.2010.11.044
103. Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, Sakato N. Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem (2003) 67(9):1883-7. doi:10.1271/bbb.67.1883
104. Yu X, Ruan X, Zhang J, Zhao Q. Celastrol induces cell apoptosis and inhibits the expression of the AML1-ETO/C-KIT oncoprotein in t(8;21) leukemia. Molecules (2016) 21:5. doi:10.3390/molecules21050574
105. Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila) (2012) 5(4):631-43. doi:10.1158/1940-6207.CAPR-11-0420
106. Uttarkar S, Dasse E, Coulibaly A, Steinmann S, Jakobs A, Schomburg C, et al. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. Blood (2016) 127(9):1173-82. doi:10.1182/blood-2015-09-668632
107. Fribley AM, Miller JR, Brownell AL, Garshott DM, Zeng Q, Reist TE, et al. Celastrol induces unfolded protein response-dependent cell death in head and neck cancer. Exp Cell Res (2015) 330(2):412-22. doi:10.1016/j.yexcr.2014.08.014
108. Feng L, Zhang D, Fan C, Ma C, Yang W, Meng Y, et al. ER stress-mediated apoptosis induced by celastrol in cancer cells and important role of glycogen synthase kinase-3beta in the signal network. Cell Death Dis (2013) 4:e715. doi:10.1038/cddis.2013.222
109. Boridy S, Le PU, Petrecca K, Maysinger D. Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells. Cell Death Dis (2014) 5:e1216. doi:10.1038/cddis.2014.182
110. Ji N, Li J, Wei Z, Kong F, Jin H, Chen X, et al. Effect of celastrol on growth inhibition of prostate cancer cells through the regulation of hERG channel in vitro. Biomed Res Int (2015) 2015:308475. doi:10.1155/2015/308475
111. Shao L, Zhou Z, Cai Y, Castro P, Dakhov O, Shi P, et al. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer. PLoS One (2013) 8(3):e58391. doi:10.1371/journal.pone.0058391
112. Sha M, Ye J, Zhang LX, Luan ZY, Chen YB. Celastrol induces apoptosis of gastric cancer cells by miR-146a inhibition of NF-kappaB activity. Cancer Cell Int (2013) 13(1):50. doi:10.1186/1475-2867-13-50
113. Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, et al. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol (2011) 164(5):1506-21. doi:10.1111/j.1476-5381.2011.01449.x
114. Ni H, Zhao W, Kong X, Li H, Ouyang J. NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis. PLoS One (2014) 9(4):e95846. doi:10.1371/journal.pone.0095846
115. Tozawa K, Sagawa M, Kizaki M. Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-kappaB pathway. Int J Oncol (2011) 39(5):1117-22. doi:10.3892/ijo.2011.1161
116. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res (2006) 66(9):4758-65. doi:10.1158/0008-5472.CAN-05-4529
117. Dai Y, Desano J, Tang W, Meng X, Meng Y, Burstein E, et al. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One (2010) 5(12):e14153. doi:10.1371/journal.pone.0014153
118. Wang XN, Wu Q, Yang X, Zhang LS, Wu YP, Lu C. Effects of Celastrol on growth inhibition of U937 leukemia cells through the regulation of the Notch1/NF-kappaB signaling pathway in vitro. Chin J Cancer (2010) 29(4):385-90. doi:10.5732/cjc.009.10526
119. Chiang KC, Tsui KH, Chung LC, Yeh CN, Chen WT, Chang PL, et al. Celastrol blocks interleukin-6 gene expression via downregulation of NF-kappaB in prostate carcinoma cells. PLoS One (2014) 9(3):e93151. doi:10.1371/journal.pone.0093151
120. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 27:693-733. doi:10.1146/annurev.immunol.021908.132641
121. Yoon MJ, Lee AR, Jeong SA, Kim YS, Kim JY, Kwon YJ, et al. Release of Ca2+ from the endoplasmic reticulum and its subsequent influx into mitochondria trigger celastrol-induced paraptosis in cancer cells. Oncotarget (2014) 5(16):6816-31. doi:10.18632/oncotarget.2256
122. Huang L, Zhang Z, Zhang S, Ren J, Zhang R, Zeng H, et al. Inhibitory action of Celastrol on hypoxia-mediated angiogenesis and metastasis via the HIF-1alpha pathway. Int J Mol Med (2011) 27(3):407-15. doi:10.3892/ijmm.2011.600
123. Ma J, Han LZ, Liang H, Mi C, Shi H, Lee JJ, et al. Celastrol inhibits the HIF-1alpha pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells. Oncol Rep (2014) 32(1):235-42. doi:10.3892/or.2014.3211
124. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res (2010) 70(5):1951-9. doi:10.1158/0008-5472.CAN-09-3201
125. Huang Y, Zhou Y, Fan Y, Zhou D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett (2008) 264(1):101-6. doi:10.1016/j.canlet.2008.01.043
126. Zhou YX, Huang YL. Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study. Chin Med J (Engl) (2009) 122(14):1666-73
127. Lerman OZ, Greives MR, Singh SP, Thanik VD, Chang CC, Seiser N, et al. Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and-independent SDF-1 induction. Blood (2010) 116(18):3669-76. doi:10.1182/blood-2009-03-213629
128. Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, Inoue M, et al. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene (2007) 26(54):7508-16. doi:10.1038/sj.onc.1210556
129. Dai Y, DeSano JT, Meng Y, Ji Q, Ljungman M, Lawrence TS, et al. Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys (2009) 74(4):1217-25. doi:10.1016/j.ijrobp.2009.03.057
130. Lee JH, Choi KJ, Seo WD, Jang SY, Kim M, Lee BW, et al. Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90. Int J Mol Med (2011) 27(3):441-6. doi:10.3892/ijmm.2011.601
131. Seo HR, Seo WD, Pyun BJ, Lee BW, Jin YB, Park KH, et al. Radiosensitization by celastrol is mediated by modification of antioxidant thiol molecules. Chem Biol Interact (2011) 193(1):34-42. doi:10.1016/j.cbi.2011.04.009
132. Wang GZ, Liu YQ, Cheng X, Zhou GB. Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents. Cancer Sci (2015) 106(7):902-8. doi:10.1111/cas.12679
133. Lo Iacono M, Monica V, Vavala T, Gisabella M, Saviozzi S, Bracco E, et al. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. Int J Cancer (2015) 136(11):2598-609. doi:10.1002/ijc.29302
134. Davenport A, Frezza M, Shen M, Ge Y, Huo C, Chan TH, et al. Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells. Int J Mol Med (2010) 25(3):465-70
135. Lu Z, Jin Y, Qiu L, Lai Y, Pan J. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett (2010) 290(2):182-91. doi:10.1016/j.canlet.2009.09.006
136. Chen M, Rose AE, Doudican N, Osman I, Orlow SJ. Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res (2009) 7(12):1946-53. doi:10.1158/1541-7786.MCR-09-0243
137. Fan XX, Li N, Wu JL, Zhou YL, He JX, Liu L, et al. Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation. Molecules (2014) 19(3):3508-22. doi:10.3390/molecules19033508
138. Jiang HL, Jin JZ, Wu D, Xu D, Lin GF, Yu H, et al. Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. Mol Biol Rep (2013) 40(7):4203-9. doi:10.1007/s11033-013-2501-y
139. Zhu H, Yang W, He LJ, Ding WJ, Zheng L, Liao SD, et al. Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells. PLoS One (2012) 7(12):e52333. doi:10.1371/journal.pone.0052333
140. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood (2007) 109(7):2727-35. doi:10.1182/blood-2006-10-050807
141. Kim Y, Kang H, Jang SW, Ko J. Celastrol inhibits breast cancer cell invasion via suppression of NF-kB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem (2011) 28(2):175-84. doi:10.1159/000331729
142. Mi C, Shi H, Ma J, Han LZ, Lee JJ, Jin X. Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9. Oncol Rep (2014) 32(6):2527-32. doi:10.3892/or.2014.3535
143. Li H, Li Y, Liu D, Sun H, Liu J. miR-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells. Cell Physiol Biochem (2013) 32(2):448-58. doi:10.1159/000354450
144. Xu J, Wu CL, Huang J. [Effect of celastrol in inhibiting metastasis of lung cancer cells by influencing Akt signaling pathway and expressing integrins]. Zhongguo Zhong Yao Za Zhi (2015) 40(6):1129-33
145. Xu J, Wu CL. [Anti-metastasis of celastrol on esophageal cancer cells and its mechanism]. Sheng Li Xue Bao (2015) 67(3):341-7
146. Zhu H, Liu XW, Cai TY, Cao J, Tu CX, Lu W, et al. Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J Pharmacol Exp Ther (2010) 334(2):489-99. doi:10.1124/jpet.110.165654
147. Yadav VR, Sung B, Prasad S, Kannappan R, Cho SG, Liu M, et al. Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med (Berl) (2010) 88(12):1243-53. doi:10.1007/s00109-010-0669-3
148. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH. Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther (2009) 8(8):2339-47. doi:10.1158/1535-7163.MCT-09-0133
149. Cleren C, Calingasan NY, Chen J, Beal MF. Celastrol protects against MPTP-and 3-nitropropionic acid-induced neurotoxicity. J Neurochem (2005) 94(4):995-1004. doi:10.1111/j.1471-4159.2005.03253.x
150. Wang J, Gines S, MacDonald ME, Gusella JF. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci (2005) 6:1. doi:10.1186/1471-2202-6-1
151. Zhang YQ, Sarge KD. Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. J Mol Med (Berl) (2007) 85(12):1421-8. doi:10.1007/s00109-007-0251-9
152. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, et al. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2010) 7:17. doi:10.1186/1742-2094-7-17
153. Kiaei M, Kipiani K, Petri S, Chen J, Calingasan NY, Beal MF. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis (2005) 2(5):246-54. doi:10.1159/000090364
154. Wang Y, Cao L, Xu LM, Cao FF, Peng B, Zhang X, et al. Celastrol ameliorates EAE induction by suppressing pathogenic T cell responses in the peripheral and central nervous systems. J Neuroimmune Pharmacol (2015) 10(3):506-16. doi:10.1007/s11481-015-9598-9
155. Abdin AA, Hasby EA. Modulatory effect of celastrol on Th1/Th2 cytokines profile, TLR2 and CD3+ T-lymphocyte expression in a relapsing-remitting model of multiple sclerosis in rats. Eur J Pharmacol (2014) 742:102-12. doi:10.1016/j.ejphar.2014.09.001
156. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol (2004) 6(11):1054-61. doi:10.1038/ncb1104-1054
157. Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med (2004) 10(10):1055-63. doi:10.1038/nm1113
158. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci (2005) 6(1):11-22. doi:10.1038/nrn1587
159. Salminen A, Lehtonen M, Paimela T, Kaarniranta K. Celastrol: molecular targets of thunder god vine. Biochem Biophys Res Commun (2010) 394(3):439-42. doi:10.1016/j.bbrc.2010.03.050
160. Chow AM, Brown IR. Induction of heat shock proteins in differentiated human and rodent neurons by celastrol. Cell Stress Chaperones (2007) 12(3):237-44. doi:10.1379/CSC-269.1
161. Ran R, Lu A, Zhang L, Tang Y, Zhu H, Xu H, et al. Hsp70 promotes TNF-mediated apoptosis by binding IKK gamma and impairing NF-kappa B survival signaling. Genes Dev (2004) 18(12):1466-81. doi:10.1101/gad.1188204
162. Weiss YG, Bromberg Z, Raj N, Raphael J, Goloubinoff P, Ben-Neriah Y, et al. Enhanced heat shock protein 70 expression alters proteasomal degradation of IkappaB kinase in experimental acute respiratory distress syndrome. Crit Care Med (2007) 35(9):2128-38. doi:10.1097/01.CCM.0000278915.78030.74
163. Chen H, Wu Y, Zhang Y, Jin L, Luo L, Xue B, et al. Hsp70 inhibits lipopolysaccharide-induced NF-kappaB activation by interacting with TRAF6 and inhibiting its ubiquitination. FEBS Lett (2006) 580(13):3145-52. doi:10.1016/j.febslet.2006.04.066
164. Choi BS, Kim H, Lee HJ, Sapkota K, Park SE, Kim S, et al. Celastrol from 'Thunder God Vine' protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson's disease. Neurochem Res (2014) 39(1):84-96. doi:10.1007/s11064-013-1193-y
165. Chen S, Gu C, Xu C, Zhang J, Xu Y, Ren Q, et al. Celastrol prevents cadmium-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network. J Neurochem (2014) 128(2):256-66. doi:10.1111/jnc.12474
166. Konieczny J, Jantas D, Lenda T, Domin H, Czarnecka A, Kuter K, et al. Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease. Neurotox Res (2014) 26(3):255-73. doi:10.1007/s12640-014-9477-9
167. Jantas D, Roman A, Kusmierczyk J, Lorenc-Koci E, Konieczny J, Lenda T, et al. The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson's disease is critically dependent on cell culture conditions. Neurotox Res (2013) 24(1):41-54. doi:10.1007/s12640-012-9374-z
168. Chow AM, Tang DW, Hanif A, Brown IR. Induction of heat shock proteins in cerebral cortical cultures by celastrol. Cell Stress Chaperones (2013) 18(2):155-60. doi:10.1007/s12192-012-0364-0
169. Chow AM, Tang DW, Hanif A, Brown IR. Localization of heat shock proteins in cerebral cortical cultures following induction by celastrol. Cell Stress Chaperones (2014) 19(6):845-51. doi:10.1007/s12192-014-0508-5
170. Zhao Y, Zhao H, Lobo N, Guo X, Gentleman SM, Ma D. Celastrol enhances cell viability and inhibits amyloid-beta production induced by lipopolysaccharide in vitro. J Alzheimers Dis (2014) 41(3):835-44. doi:10.3233/JAD-131799
171. Boje KM, Arora PK. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res (1992) 587(2):250-6. doi:10.1016/0006-8993(92)91004-X
172. Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med (2006) 38(4):333-47. doi:10.1038/emm.2006.40
173. Jung HW, Chung YS, Kim YS, Park YK. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med (2007) 39(6):715-21. doi:10.1038/emm.2007.78
174. Hafizi Abu Bakar M, Kian Kai C, Wan Hassan WN, Sarmidi MR, Yaakob H, Zaman Huri H. Mitochondrial dysfunction as a central event for mechanisms underlying insulin resistance: the roles of long chain fatty acids. Diabetes Metab Res Rev (2015) 31(5):453-75. doi:10.1002/dmrr.2601
175. Abu Bakar MH, Cheng KK, Sarmidi MR, Yaakob H, Huri HZ. Celastrol protects against antimycin A-induced insulin resistance in human skeletal muscle cells. Molecules (2015) 20(5):8242-69. doi:10.3390/molecules20058242
176. Kim JE, Lee MH, Nam DH, Song HK, Kang YS, Lee JE, et al. Celastrol, an NF-kappaB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice. PLoS One (2013) 8(4):e62068. doi:10.1371/journal.pone.0062068
177. Han LP, Li CJ, Sun B, Xie Y, Guan Y, Ma ZJ, et al. Protective effects of celastrol on diabetic liver injury via TLR4/MyD88/NF-kappaB signaling pathway in type 2 diabetic rats. J Diabetes Res (2016) 2016:2641248. doi:10.1155/2016/2641248
178. Guan Y, Cui ZJ, Sun B, Han LP, Li CJ, Chen LM. Celastrol attenuates oxidative stress in the skeletal muscle of diabetic rats by regulating the AMPK-PGC1alpha-SIRT3 signaling pathway. Int J Mol Med (2016) 37(5):1229-38. doi:10.3892/ijmm.2016.2549
179. Grant CW, Moran-Paul CM, Duclos SK, Guberski DL, Arreaza-Rubin G, Spain LM. Testing agents for prevention or reversal of type 1 diabetes in rodents. PLoS One (2013) 8(8):e72989. doi:10.1371/journal.pone.0072989
180. Zhang J, Li CY, Xu MJ, Wu T, Chu JH, Liu SJ, et al. Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats. J Ethnopharmacol (2012) 144(1):195-200. doi:10.1016/j.jep.2012.09.005
181. Ju SM, Youn GS, Cho YS, Choi SY, Park J. Celastrol ameliorates cytokine toxicity and pro-inflammatory immune responses by suppressing NF-kappaB activation in RINm5F beta cells. BMB Rep (2015) 48(3):172-7. doi:10.5483/BMBRep.2015.48.3.147
182. Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. Cell (2015) 161(5):999-1011. doi:10.1016/j.cell.2015.05.011
183. Aragones G, Ardid-Ruiz A, Ibars M, Suarez M, Blade C. Modulation of leptin resistance by food compounds. Mol Nutr Food Res (2016) 60(8):1789-803. doi:10.1002/mnfr.201500964
184. Ma X, Xu L, Alberobello AT, Gavrilova O, Bagattin A, Skarulis M, et al. Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1alpha transcriptional axis. Cell Metab (2015) 22(4):695-708. doi:10.1016/j.cmet.2015.08.005
185. Zhu F, Li C, Jin XP, Weng SX, Fan LL, Zheng Z, et al. Celastrol may have an anti-atherosclerosis effect in a rabbit experimental carotid atherosclerosis model. Int J Clin Exp Med (2014) 7(7):1684-91
186. Gu L, Bai W, Li S, Zhang Y, Han Y, Gu Y, et al. Celastrol prevents atherosclerosis via inhibiting LOX-1 and oxidative stress. PLoS One (2013) 8(6):e65477. doi:10.1371/journal.pone.0065477
187. Lu C, Yu X, Zuo K, Zhang X, Cao C, Xu J, et al. Tripterine treatment improves endothelial progenitor cell function via integrin-linked kinase. Cell Physiol Biochem (2015) 37(3):1089-103. doi:10.1159/000430234
188. Lu C, Zhang X, Zhang D, Pei E, Xu J, Tang T, et al. Short time tripterine treatment enhances endothelial progenitor cell function via heat shock protein 32. J Cell Physiol (2015) 230(5):1139-47. doi:10.1002/jcp.24849
189. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des (2007) 13(1):119-26. doi:10.2174/138161207779313731
190. Rybak LP, Ramkumar V. Ototoxicity. Kidney Int (2007) 72(8):931-5. doi:10.1038/sj.ki.5002434
191. Francis SP, Kramarenko II, Brandon CS, Lee FS, Baker TG, Cunningham LL. Celastrol inhibits aminoglycoside-induced ototoxicity via heat shock protein 32. Cell Death Dis (2011) 2:e195. doi:10.1038/cddis.2011.76
192. Kim HJ, So HS, Lee JH, Lee JH, Park C, Park SY, et al. Heme oxygenase-1 attenuates the cisplatin-induced apoptosis of auditory cells via down-regulation of reactive oxygen species generation. Free Radic Biol Med (2006) 40(10):1810-9. doi:10.1016/j.freeradbiomed.2006.01.018
193. Qi X, Qin J, Ma N, Chou X, Wu Z. Solid self-microemulsifying dispersible tablets of celastrol: formulation development, characterization and bioavailability evaluation. Int J Pharm (2014) 472(1-2):40-7. doi:10.1016/j.ijpharm.2014.06.019
194. Li Z, Yao L, Li J, Zhang W, Wu X, Liu Y, et al. Celastrol nanoparticles inhibit corneal neovascularization induced by suturing in rats. Int J Nanomedicine (2012) 7:1163-73. doi:10.2147/IJN.S27860
195. Rita Cascão TC, Goncalves J, Moita L, Fonseca J. Efficacy and Safety of Oral Administration of Pure Celastrol in AIA Rats. Madrid: EULAR (2017). Abstract Book: Annals of Rheumatic Diseases ARD
196. Bai JP, Shi YL, Fang X, Shi QX. Effects of demethylzeylasteral and celastrol on spermatogenic cell Ca2+ channels and progesterone-induced sperm acrosome reaction. Eur J Pharmacol (2003) 464(1):9-15. doi:10.1016/S0014-2999(03)01351-7
197. Sun H, Liu X, Xiong Q, Shikano S, Li M. Chronic inhibition of cardiac Kir2.1 and HERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking. J Biol Chem (2006) 281(9):5877-84. doi:10.1074/jbc.M600072200
198. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2001) 25(7):1341-57. doi:10.1016/S0278-5846(01)00192-0
199. Yu X, Tao W, Jiang F, Li C, Lin J, Liu C. Celastrol attenuates hypertension-induced inflammation and oxidative stress in vascular smooth muscle cells via induction of heme oxygenase-1. Am J Hypertens (2010) 23(8):895-903. doi:10.1038/ajh.2010.75
200. Aqil F, Kausar H, Agrawal AK, Jeyabalan J, Kyakulaga AH, Munagala R, et al. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp Mol Pathol (2016) 101(1):12-21. doi:10.1016/j.yexmp.2016.05.013
201. Zhang X, Zhang T, Zhou X, Liu H, Sun H, Ma Z, et al. Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation. J Pharm Sci (2014) 103(6):1711-9. doi:10.1002/jps.23967
202. Sanna V, Chamcheu JC, Pala N, Mukhtar H, Sechi M, Siddiqui IA. Nanoencapsulation of natural triterpenoid celastrol for prostate cancer treatment. Int J Nanomedicine (2015) 10:6835-46. doi:10.2147/IJN.S93752
203. Boridy S, Soliman GM, Maysinger D. Modulation of inflammatory signaling and cytokine release from microglia by celastrol incorporated into dendrimer nanocarriers. Nanomedicine (Lond) (2012) 7(8):1149-65. doi:10.2217/nnm.12.16
204. Wolfram J, Suri K, Huang Y, Molinaro R, Borsoi C, Scott B, et al. Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells. J Microencapsul (2014) 31(5):501-7. doi:10.3109/02652048.2013.879932
205. Huang Y, Zhou D, Hang T, Wu Z, Liu J, Xu Q, et al. Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol. Anticancer Drugs (2012) 23(5):515-24. doi:10.1097/CAD.0b013e3283514b68
206. Song J, Shi F, Zhang Z, Zhu F, Xue J, Tan X, et al. Formulation and evaluation of celastrol-loaded liposomes. Molecules (2011) 16(9):7880-92. doi:10.3390/molecules16097880
207. Peng X, Wang J, Song H, Cui D, Li L, Li J, et al. Optimized preparation of celastrol-loaded polymeric nanomicelles using rotatable central composite design and response surface methodology. J Biomed Nanotechnol (2012) 8(3):491-9. doi:10.1166/jbn.2012.1398
208. Li Z, Wu X, Li J, Yao L, Sun L, Shi Y, et al. Antitumor activity of celastrol nanoparticles in a xenograft retinoblastoma tumor model. Int J Nanomedicine (2012) 7:2389-98. doi:10.2147/IJN.S29945
209. Yuan L, Liu C, Chen Y, Zhang Z, Zhou L, Qu D. Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model. Int J Nanomedicine (2013) 8:4339-50. doi:10.2147/IJN.S51621
210. Chen Y, Zhou L, Yuan L, Zhang ZH, Liu X, Wu Q. Formulation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers. Int J Nanomedicine (2012) 7:3023-32. doi:10.2147/IJN.S32476
211. Zhou L, Chen Y, Zhang Z, He J, Du M, Wu Q. Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine. Pharmazie (2012) 67(4):304-10
212. Niemela E, Desai D, Nkizinkiko Y, Eriksson JE, Rosenholm JM. Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells. Eur J Pharm Biopharm (2015) 96:11-21. doi:10.1016/j.ejpb.2015.07.009
213. Shanmugam MK, Nguyen AH, Kumar AP, Tan BK, Sethi G. Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: potential role in prevention and therapy of cancer. Cancer Lett (2012) 320(2):158-70. doi:10.1016/j.canlet.2012.02.037
214. Wang S, Wu X, Tan M, Gong J, Tan W, Bian B, et al. Fighting fire with fire: poisonous Chinese herbal medicine for cancer therapy. J Ethnopharmacol (2012) 140(1):33-45. doi:10.1016/j.jep.2011.12.041
215. Abbas S, Bhoumik A, Dahl R, Vasile S, Krajewski S, Cosford ND, et al. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res (2007) 13(22 Pt 1):6769-78. doi:10.1158/1078-0432.CCR-07-1536
216. Sun H, Xu L, Yu P, Jiang J, Zhang G, Wang Y. Synthesis and preliminary evaluation of neuroprotection of celastrol analogues in PC12 cells. Bioorg Med Chem Lett (2010) 20(13):3844-7. doi:10.1016/j.bmcl.2010.05.066
217. Wei W, Wu S, Wang X, Sun CK, Yang X, Yan X, et al. Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. Oncotarget (2014) 5(14):5819-31. doi:10.18632/oncotarget.2171
218. Wu J, Zhou Y, Wang L, Zuo J, Zhao W. Terpenoids from root bark of Celastrus orbiculatus. Phytochemistry (2012) 75:159-68. doi:10.1016/j.phytochem.2011.11.023
219. Tang K, Huang Q, Zeng J, Wu G, Huang J, Pan J, et al. Design, synthesis and biological evaluation of C6-modified celastrol derivatives as potential antitumor agents. Molecules (2014) 19(7):10177-88. doi:10.3390/molecules190710177
220. Tang WJ, Wang J, Tong X, Shi JB, Liu XH, Li J. Design and synthesis of celastrol derivatives as anticancer agents. Eur J Med Chem (2015) 95:166-73. doi:10.1016/j.ejmech.2015.03.039